Magic mushroom compound tested for hard-to-treat mental health struggles

NCT ID NCT06442423

Recruiting now Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study at Yale is testing whether a single 25 mg dose of psilocybin is safe and tolerable for people whose daily life is impaired by mood, anxiety, trauma, or addiction symptoms. Fifty participants will receive the drug openly (everyone knows they get it) and be followed for up to 6 weeks, with optional longer follow-up. The goal is to see if psilocybin can reduce symptoms and improve functioning, even in people with multiple conditions who are often excluded from other studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat mood, anxiety, trauma, or addiction symptoms that cause real-life disability.
What could go wrong: This is a very early, small, open-label study with no placebo group, so results may not be reliable. Psilocybin can cause intense psychological effects and is not yet approved for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder Behavior, Addictive Depression major depressive disorder mood disorder obsessive-compulsive disorder obsessive-compulsive personality disorder post-traumatic stress disorder substance abuse substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANXIETY DEPRESSION - MAJOR DEPRESSIVE DISORDER OCD PTSD PTSD SYMPTOMS SUBSTANCE USE SUBSTANCE USE DISORDER (SUD) TRANSDIAGNOSTIC

Contacts and locations

Locations

Connecticut Mental Health Center - Yale School of Medicine
RECRUITING

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.